Guía de práctica clínica para el manejo del cáncer de cuello uterino invasivo

Objectives

The 2014 Colombian clinical practice guideline seeks to improve the integrated management of invasive cervical cancer through evidence-based, stage-specific recommendations that reduce disease progression, mortality and treatment-related morbidity, while strengthening quality assurance in clinical care.[1]It applies to women with epithelial cervical cancer, including squamous-cell carcinoma and adenocarcinoma at any stage, and excludes metastatic tumours affecting the cervix, non-epithelial cervical cancer and primary cervical melanoma.[2]

• Provide recommendations for diagnosis, surgical treatment, chemotherapy, radiotherapy, follow-up and rehabilitation across the cervical-cancer care pathway.[1][3]
• Match treatment to disease stage, clinical circumstances and fertility preferences, including conservative surgery for appropriately selected women with stage IA1, IA2 or IB1 disease.[4][5]
• Support standard surgical management with total hysterectomy for stage IA1, modified radical hysterectomy for IA2 and radical hysterectomy for IB1, alongside selective lymph-node assessment and fertility-preserving options.[4]
• Use concurrent cisplatin and radiotherapy for non-metastatic locally advanced disease, consider carboplatin with radiotherapy for renal failure, and consider bevacizumab for persistent or systemic recurrent disease in specified circumstances.[5][6][7]
• Adopt three-dimensional conformal radiotherapy as the standard radiotherapy technique to limit toxicity to surrounding tissues, while considering intensity-modulated radiotherapy in authorised centres for selected postoperative or nodal-involvement cases.[8]
• Improve prevention and early detection by strengthening screening coverage and quality, definitive diagnosis, follow-up of high-grade lesions, timely treatment and access to care.[9][10]
• Contribute to Colombia’s Decennial Plan for Cancer Control 2012–2021 through improved timely diagnosis, treatment access, continuity of care and outcomes for women with cervical cancer.[11][12]
• Support patient-centred care through clear information, participation in treatment decisions, psychosocial support and humanised diagnosis notification and treatment.[13][14][15]

Implementation

Implementation is framed as a systematic process that connects evidence with clinical practice, identifies contextual barriers and facilitators, and uses education, specialised tools, dissemination and monitoring to support adoption across the health system.[16]The approach involves national institutions, territorial authorities, insurers, healthcare providers, professional bodies, educational institutions, patients and families.[11][17][12][18][19]

• Coordinate national implementation through the Ministry of Health and Social Protection, the Institute for Health Technology Assessment, the National Cancer Institute, the National Institute of Health, territorial authorities, health-promoting enterprises and healthcare providers.[11][17][12]
• Assign the Institute for Health Technology Assessment responsibility for dissemination tools, territorial implementation nodes, technical assistance, implementation research, monitoring and recording progress with the Ministry.[11]
• Assign the National Cancer Institute roles in policy advice, dissemination, professional competencies, research, educational materials, clinical training and patient and family education.[11][17]
• Maintain national surveillance of cervical-cancer incidence and mortality through the National Institute of Health, including departmental information analysis and technical assistance on surveillance.[17]
• Require territorial authorities to develop local implementation plans, assist municipalities, verify oncology-service authorisation conditions, train personnel and oversee implementation against cancer-control targets.[17][12]
• Require health-promoting enterprises to coordinate care networks, reduce administrative barriers and partial authorisations, maintain information systems, supervise providers, ensure follow-up and report indicators.[12]
• Require healthcare providers to establish institutional implementation plans, align information systems with standards and indicators, report diagnosis and treatment information to insurers, and form multidisciplinary implementation teams.[18][19]
• Use combined dissemination strategies, including virtual media, institutional communication, scientific societies, regional forums, printed materials, reminders, checklists, electronic tools, flowcharts, educational meetings and patient-focused activities.[20][21][22][23]
• Address barriers such as fragmented care, delayed authorisations, remote access constraints, shortages of specialist staff and equipment, uneven technology availability, weak information systems and limited psychosocial support.[24][25][26][27]
• Monitor implementation through process, outcome and efficiency indicators, including timeliness and quality of diagnosis, access, treatment initiation, prognosis, survival, adherence and continuity of care.[16][28][11]
• Incorporate guideline indicators into the Health Care Quality Observatory and the Health Information System for Social Protection, with insurers reporting relevant diagnosis and management indicators to the high-cost account.[11][12]
• Use annual provider reporting and a stated 100% reference target for the proportion of eligible women receiving recommended stage-specific surgical and non-surgical treatment.[29][30][6][7][8]
• Evaluate longer-term impact through mortality trends, cancer surveillance and information systems, with a five-year assessment of mortality from invasive cervical cancer envisaged in the implementation framework.[23]

Monitoring & Evaluation

The guideline establishes an implementation, monitoring and accountability framework for invasive cervical cancer care, combining evidence appraisal, clinical indicators, cancer surveillance, quality assurance and institutional oversight. It also requires periodic updating, initially planned within five years of development.[31][32]

• Monitor implementation through process and outcome indicators, although the introductory implementation material does not provide a complete indicator specification.[16]
• Track population outcomes including cervical-cancer mortality, screening coverage, cytology quality, follow-up after high-grade lesions, service availability, timely diagnosis, treatment access, prognosis and survival.[9][10][28]
• Measure treatment adherence annually using provider reports, with a stated 100% target for eligible women receiving the stage-specific surgical or non-surgical recommendation.[33][29][30][6][7][8]
• Monitor treatment initiation, adherence, recurrence, overall and progression-free survival, adverse events, hospital-acquired infections and procedure-related complications; treatment initiation should not exceed 30 days.[23][33]
• Incorporate guideline indicators into the Health Care Quality Observatory and the Health Information System for Social Protection, with responsibilities for system actors to collect implementation data.[11]
• Require health-promoting enterprises to report diagnosis and management indicators to the high-cost account, supervise provider networks and continuity of care, and reduce administrative barriers.[12]
• Maintain national surveillance of cervical-cancer incidence and mortality through the National Institute of Health, which is also responsible for analysing surveillance information from all departments.[17]
• Assign territorial authorities responsibility for local implementation plans, compliance monitoring, oncology-service authorisation checks and oversight of Decennial Plan for Cancer Control targets.[17][12]
• Use inspection, monitoring and control by the National Health Superintendence for insurers, providers and independent professionals in relation to guideline implementation, integrated care and access barriers.[28]
• Embed guideline compliance and monitoring within institutional authorisation, accreditation, certification, mandatory quality systems, complaint-resolution processes and clinical case-review committees.[28][13][14]
• Establish multidisciplinary institutional implementation teams and adapt provider information systems to implementation standards and indicators.[18][19]
• Evaluate implementation effectiveness, sustained improvement, resource use and clinical outcomes, while recognising that the source does not consistently specify indicator definitions, reporting intervals, sanctions or detailed evaluation designs.[34][18][35][19]
• Apply external methodological quality review using AGREE II for clinical content and CHEERS for the economic evaluation, and reassess tracer recommendations and their indicators during updating.[31][32]

Costing & Financing

The guideline was financed exclusively through Colombian public resources under Agreement 550/2013–2014, project code 210-156-33574. Funding covered technical and methodological work, implementation planning, economic evaluation, patient consultation, consensus logistics, administration and follow-up, but no total guideline budget or allocation by activity is reported.[36][31]

• Recognise major resource barriers to implementation, including limited specialist workforce, uneven access to oncology centres and radiotherapy technology, fragmented authorisations, insufficient infrastructure and gaps in coverage for procedures, medicines and patient transport or accommodation.[24][25][26][20][37]
• Allocate institutional resources for dissemination, implementation, evaluation and control of the guideline, although the required amounts and funding sources are not specified.[19]
• Address operating costs of screening programmes, including infrastructure, workforce, diagnostic follow-up and treatment of women with abnormal cytology; no monetary estimates are supplied for these programme costs.[38][3]
• Recognise that three-dimensional conformal radiotherapy was assessed as 50% more costly than conventional radiotherapy and intensity-modulated radiotherapy as 100% more costly; neither was included in the benefits plan at the time described.[39]
• Undertake economic evaluation of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy against conventional radiotherapy and the national willingness-to-pay threshold.[40][41]
• Use direct-cost economic evaluation of bevacizumab from a third-party payer perspective, covering medicines, preparation, administration, complications and adverse events. Costs and health outcomes were discounted annually at 3.5%.[42][43]
• Find that adding bevacizumab to chemotherapy was more effective but not cost-effective in Colombia at the threshold of three times gross domestic product per capita: the incremental cost per life-year gained was 202,645,448.94, compared with a threshold of 45,026,379.[44]
• Identify cost-effectiveness for bevacizumab in sensitivity analysis if its treatment-cycle cost fell to 3,412,000 or willingness to pay exceeded 200,000,000 per additional life-year gained.[44][45]
• Recognise that further economic studies are needed for alternatives to cisplatin, neoadjuvant chemotherapy and other interventions, while budgets, funding gaps, resource-mobilisation plans and programme-wide financing arrangements remain unspecified.[46][47][48][49]